Chronic hyperglycemia leads to diminished glucose‐stimulated insulin secretion and increased insulin resistance, and resolving this glucose toxicity is a key to the treatment of T2DM, as the decline in insulin secretion and insulin sensitivity will lead to further hyperglycemia. The gene discussed is INS; the disease is Insulin resistance.